DEA Rescheduling Hearing Exposes Procedural Gaps, Observer Reports

Hearing Convened Under DEA Rulemaking Authority

The DEA convened the hearing pursuant to 21 CFR §1308.44(d), which mandates an evidentiary record when rescheduling a controlled substance. Ten business days in July 2026. Testimony came from pharmacologists, physicians, and policy experts. Under the Controlled Substances Act, Schedule III substances must demonstrate accepted medical use, lower abuse potential than Schedule I or II drugs, and moderate or low physical dependence risk. The hearing record will inform the DEA Administrator's final rule, expected in Q4 2026.

Max Jackson, a cannabis-industry analyst who observed the proceedings, noted that the majority of witnesses cited peer-reviewed literature and FDA data but acknowledged minimal direct experience cultivating or handling live cannabis plants. This gap isn't disqualifying under DEA evidentiary standards, which prioritize scientific credentials over operational expertise, but it raises questions about the completeness of the administrative record.

Witness Pool Skewed Toward Academic Credentials

Of the witnesses who testified, fewer than 15 percent disclosed hands-on cultivation or dispensary operations experience. The remainder held advanced degrees in pharmacology, toxicology, or public health. Jackson observed that "almost none of them have grown" cannabis, a detail that became conspicuous during cross-examination on terpene profiles, harvest timing, and cannabinoid variance by phenotype.

A strict reading of 21 CFR §1308.44(e) shows the DEA isn't required to balance academic and practitioner testimony. The regulation specifies only that witnesses must provide "relevant and material" evidence. Yet the absence of cultivator or dispensary-operator testimony may limit the record's utility in addressing operational compliance questions that arise post-rescheduling, particularly around Good Manufacturing Practice (GMP) standards and state-federal licensing conflicts.

Procedural Irregularities in Cross-Examination

The hearing's cross-examination phase deviated from standard APA adjudication protocols in at least two respects. First, the presiding Administrative Law Judge (ALJ) imposed a 15-minute hard cap on cross-examination per witness, a constraint not specified in the NPRM or the hearing notice published in the Federal Register. Second, several witnesses were permitted to submit supplemental written statements post-testimony without opportunity for rebuttal cross-examination.

Under 5 USC §556(d), parties in an APA hearing are entitled to "conduct such cross-examination as may be required for a full and true disclosure of the facts." The 15-minute cap and post-hearing submissions arguably narrow that right. No party filed a formal objection during the proceeding, but the procedural choices may form the basis for judicial review if the final rule is challenged in federal court.

Evidentiary Record Leans on FDA and HHS Data

The bulk of the evidentiary record consisted of the FDA's 2023 scientific review and the HHS rescheduling recommendation transmitted to DEA in August 2023. Witnesses repeatedly cited the FDA's finding that cannabis has "currently accepted medical use" and a "lower abuse potential" than Schedule I or II substances. The DEA isn't bound by the HHS recommendation under 21 USC §811(b), but the agency has never rejected an HHS rescheduling request in the modern CSA era.

Jackson noted that the hearing produced little new primary data. Most testimony restated conclusions from the FDA review or cited studies already in the public record. The lack of novel evidence may expedite the DEA's final rule but also limits the hearing's value as a fact-finding exercise.

State-Federal Licensing Conflicts Unaddressed

The hearing didn't substantively address how Schedule III classification would interact with state cannabis licensing regimes. Under Schedule III, cannabis would remain a controlled substance subject to DEA registration under 21 USC §823. State-licensed dispensaries and cultivators currently operate without federal registration, relying on the DOJ's non-enforcement posture articulated in the 2013 Cole Memo (rescinded 2018 but de facto restored under current policy).

If cannabis moves to Schedule III, operators may face a choice: apply for DEA registration (triggering federal oversight and GMP compliance) or continue state-only operations with uncertain federal enforcement risk. The hearing record contains no testimony on this operational fork, a gap that state regulators and MSOs have flagged in public comments. For full background on the rescheduling timeline and outstanding regulatory questions, see the CannIntel topic hub on DEA rescheduling.

Next Steps and Timeline for Final Rule

The DEA will compile the hearing transcript and written submissions into a final administrative record by September 2026. The Administrator's final rule is expected in Q4 2026, with a 60-day effective date following Federal Register publication. If the rule moves cannabis to Schedule III, the change would take effect in early 2027, triggering immediate tax implications under IRC §280E (which disallows business deductions for Schedule I and II substances but not Schedule III).

The procedural irregularities documented by Jackson may not meet the threshold for judicial reversal under the Administrative Procedure Act's "arbitrary and capricious" standard, but they provide a potential avenue for challenge if industry groups or advocacy organizations seek to delay or modify the final rule. Next signal: publication of the official hearing transcript, expected by August 15, 2026.